[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354401-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354401-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","colonoscope-derived-mucus-as-a-novel-high-fidelity-reservoir-for-kras-mutated-precancerous-colorectal-neoplasia-detection","Colonoscope-derived mucus as a novel high-fidelity reservoir for KRAS-mutated precancerous colorectal neoplasia detection","","Current colorectal cancer screening has limited sensitivity for precancerous lesions, and blood-based liquid biopsies are constrained by systemic dilution. A prospective pilot study evaluated whether colonoscope-derived mucus can provide high-fidelity cell-free DNA for detecting KRAS-mutated colorectal neoplasia. Mucus cfDNA (N=43) was analyzed for KRAS codon 12 mutations, and diagnostic performance was compared with histology, FIT, and CEA across VAF thresholds.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/colonoscope-derived-mucus-as-a-novel-high-fidelity-reservoir-for-kras-mutated-precancerous-colorectal-neoplasia-detection/354401/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/colonoscope-derived-mucus-as-a-novel-high-fidelity-reservoir-for-kras-mutated-precancerous-colorectal-neoplasia-detection/354401.png","ImageObject",300,407,{"name":42,"@type":43},"Ben ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of using colonoscope-derived mucus in this study?","Question",{"text":63,"@type":64},"To evaluate whether colonoscope-derived mucus can serve as a high-fidelity source of cell-free DNA for detecting KRAS-mutated precancerous colorectal neoplasia, addressing limited sensitivity of current screening methods.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were KRAS mutations detected from mucus cfDNA?",{"text":68,"@type":64},"Mucus samples collected from the colonoscope sheath were analyzed for KRAS codon 12 mutations using a competitive PCR assay, and performance was assessed using variant allele frequency thresholds.",{"name":70,"@type":61,"acceptedAnswer":71},"What diagnostic performance did the mucus cfDNA show at VAF thresholds?",{"text":72,"@type":64},"At VAF >0.1%, mucus cfDNA achieved 80.0% sensitivity for colorectal neoplasia, outperforming FIT (40.0%) and CEA (10.0%), with specificity decreasing at lower thresholds likely due to inflammatory confounders.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354401,1790829501,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},2336478951081,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Translational Oncology 71 (2026) 102872  \nContents lists available at ScienceDirect  \nTranslational Oncology  \njournal [homepage:](homepage: www.elsevier.com/locate/tranon)[ www.elsevier.com/locate/tranon](homepage: www.elsevier.com/locate/tranon)  \n| Original Research\u003Cbr>Colonoscope-derived mucus as a novel high-fidelity reservoir for\u003Cbr>KRAS-mutated precancerous colorectal neoplasia detection Fang-Chin Hsua , Ta-Wei Pub, Jung-Chun Linc, Chao-Yang Chena,*\u003Cbr>a Division of Colorectal Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan\u003Cbr>b Division of Colon and Rectal Surgery, Department of Surgery, Songshan Branch, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan c Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords: Colorectal cancer KRAS mutation Cell-free DNA Biomarker Liquid biopsy |  | Background and Aims: Current colorectal cancer (CRC) screening methods have limited sensitivity for precancerous lesions. Blood-based liquid biopsies are constrained by systemic dilution, highlighting the need for localized, minimally invasive molecular approaches. We evaluated whether colonoscope-derived mucus serves asa high-fidelity source of cell-free DNA (cfDNA) for detecting KRAS-mutated colorectal neoplasia.\u003Cbr>Methods: In this prospective pilot study, mucus samples (N = 43) were collected from the colonoscope sheath during routine colonoscopy. cfDNA was analyzed for KRAS codon 12 mutations using a competitive PCR assay. Diagnostic performance at variant allele frequency (VAF) thresholds (>1% and >0.1%) was compared with histology, fecal immunochemical testing (FIT), and carcinoembryonic antigen (CEA).\u003Cbr>Results: At VAF >0.1%, mucus cfDNA achieved 80.0% sensitivity for colorectal neoplasia, outperforming FIT (40.0%) and CEA (10.0%, p = 0.005). Sensitivity reached 100% for adenocarcinoma (n=2) and 75.0% for advanced precancerous colorectal lesions. Specificity decreased to 29.6% at lower thresholds, likely due to inflammatory confounders. Importantly, KRAS mutations were detected in visually inconspicuous mucosa. Conclusions: Colonoscope-derived mucus is a promising localized cfDNA source for detecting early colorectal neoplasia. This approach may serve as a colonoscopy-integrated adjunct within existing screening pathways and may support post-procedure risk stratification and surveillance optimization. |\n\nIntroduction  \nColorectal cancer (CRC) remains a significant global health burden, ranking as the fourth most common malignancy and the third leading cause of cancer-related mortality worldwide. According to GLOBOCAN 2022 estimates, approximately 1.93 million new CRC cases and 930,000 deaths occurred in 2022. Projections indicate a 71% increase in new cases by 2040, driven by aging populations and evolving lifestyle factors, particularly in low- and middle-income countries [1]. In Asia, incidence rates are rising in high-income regions such as Japan and South Korea, while in Western nations like the United States, over 150, 000 new cases are anticipated annually by 2025 [1,2]. Taiwan exemplifies this trend; CRC is established as the second most common cancer, with age-standardized incidence rates of 43.12 per 100,000 for men and 29.31 per 100,000 for women (2020 data). Projections for Taiwan estimate a 71% rise in incidence and an 85% increase in mortality by 2040 [3,4]. Notably, Taiwan reports one of the highest incidence rates  \nglobally among individuals aged 40–49 years, underscoring the critical need for earlier and more effective screening strategies [3].  \nCurrent guidelines from the US Preventive Services Task Force and American Cancer Society recommend initiating screening at age 45 years for average-risk individuals, typically utilizing annual fecal im","cbCaigSV5no1bc2q","https://ap.wps.com/l/cbCaigSV5no1bc2q","pdf",1555523,"English","# Background and Aims\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Current screening landscape and limitations\n## Clinical rationale for localized cfDNA detection","[{\"question\":\"What was the purpose of using colonoscope-derived mucus in this study?\",\"answer\":\"To evaluate whether colonoscope-derived mucus can serve as a high-fidelity source of cell-free DNA for detecting KRAS-mutated precancerous colorectal neoplasia, addressing limited sensitivity of current screening methods.\"},{\"question\":\"How were KRAS mutations detected from mucus cfDNA?\",\"answer\":\"Mucus samples collected from the colonoscope sheath were analyzed for KRAS codon 12 mutations using a competitive PCR assay, and performance was assessed using variant allele frequency thresholds.\"},{\"question\":\"What diagnostic performance did the mucus cfDNA show at VAF thresholds?\",\"answer\":\"At VAF \\u003e0.1%, mucus cfDNA achieved 80.0% sensitivity for colorectal neoplasia, outperforming FIT (40.0%) and CEA (10.0%), with specificity decreasing at lower thresholds likely due to inflammatory confounders.\"}]","Colonoscope-derived mucus as a novel high-fidelity reservoir for KRAS-mutated precancerous colorectal neoplasia detection | PDF",1790110458,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49866c9dd001ac1f517bd1e30ba9392f.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8dd202fc1287a1b158ebb743494893d7.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7051a286f091bbcb650b9cecb8658aa9.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eaea81052e46193c1d05d69ac5b5251a.webp",980,1306]